Sean Reilly, DAIC Publisher

Sean Reilly is healthcare brands group publisher (Imaging Technology News and Diagnostic and Interventional Cardiology) at Scranton Gillette Communications.
 

Blog | Sean Reilly, DAIC Publisher | January 09, 2013

Innovation Exasperation

In a recent LinkedIn Medical Device Group posting, it was noted that DuVal & Associates, P.A. filed a Citizen Petition and Petition for Stay of Action with the FDA, on behalf of the Minnesota Medical Device Alliance (MMDA). See: http://medgroup.biz/FDA-petition

The petition challenges the FDA's practices and interpretations for reviewing 510(k)s and asks the Commissioner to stay the implementation of “Draft Guidance: Evaluating Substantial Equivalence in Premarket Notifications [510(k)],” dated December 27, 2011. It seeks reversion to older guidance until FDA addresses:

Its practice of “stage-gating” reviews (because it leads to an inevitable FDA request to pursue the de novo path); Its interpretation of “general versus specific intended use,” now applied so narrowly that FDA considers almost every new indication for a 510(k) device to be a new intended use; Its interpretation of clinical utility/benefit as part of the substantial equivalence (SE) criteria (because it essentially allows FDA to determine which devices practitioners should use); Its inappropriate use of statutes and regulatory matters extraneous to the SE decision (e.g., cGMP/Quality Systems, MDR, FD&C Act advertising and promotion, and OSHA regulations or CDC guidance); Its application of risk mitigation and “assurance case” principles to 510(k) clearance criteria; Its interpretation when a device has a new technological characteristic which raises new questions of safety and effectiveness; Its failure in stage-gated reviews to review performance data to determine same intended use / technological characteristics and if new safety and effectiveness questions need to be asked; Its practice of dictating the non-clinical and clinical performance data an applicant must generate (instead of reviewing submitted data at face value for an SE decision); and, Its approach to “whistleblowing,” which can lead to risk-averseness for political, not safety, reasons.

 

The petition seems on the mark. Medical device companies are under enormous financial pressures with difficult economies both domestically and abroad. Add to this the 2.3% medical device tax on gross revenues and a highly bureaucratic, overbearing (if you agree with this petition) FDA and you can’t help but envision difficult times ahead for our industry. Innovative small and midsize companies are struggling, and the government and the FDA aren’t helping matters by treating innovation as the problem. Many on the device side seem unable or unwilling to challenge the FDA bureaucracy.  Win the battle but lose the war, perhaps? As one CEO recently shared, "Challenging [the FDA] might make me feel better but it won't resolve the problem." A real shame as, according to this petition, the FDA and some of its policies need to be challenged.

I agree with this petition that the United States may fall behind other countries in having access to state-of-the-art medical devices while they still are state-of-the-art. That ship may have already sailed, in fact. I also agree that innovation – something we have always embraced and encouraged as a great nation – is being thwarted rather than supported. Healthcare consumers and innovative device companies are suffering and will continue to do so if changes aren’t made. 

Despite said doom and gloom, some innovative, well-managed companies will blast through the aforementioned roadblocks and become stronger, particularly as competition drops off. But I’m concerned that it's going to be mostly the largest companies that survive, and innovation might not always be their strongest suit. I’m also concerned that, as competition disappears, medical device prices will increase – not good for consumers or our Healthcare System.

There is a symbiotic relationship between healthcare providers, healthcare consumers, device manufacturers, our government and the FDA. Sadly, the later have too much power and our system, as this petition suggests, is out of balance and in need of correction. If you agree, beat the drums!

Related Content

HHS, health information sharing, funding opportunities, data standards
News | Information Technology| May 16, 2016
The U.S. Department of Health and Human Services (HHS) released two funding opportunities from the Office of the...
anayltics software, health analytics, cath lab analytics, lumedex
Sponsored Content | Case Study | Analytics Software| May 13, 2016
The hospitals of UnityPoint Health – Des Moines operate under a shared vision “Best outcome for every patient, every
Sponsored Content | Videos | HIMSS| May 13, 2016
ITN/DAIC Editor Dave Fornell takes a tour of some of the most innovative new trends and health information t
Radiation dose management, radiation dose monitoring, X-ray dose

Analytics from Sectra’s radiation dose monitoring software showing procedures where dose levels were higher than normal for various X-ray modalities. 

Feature | Radiation Dose Management| May 12, 2016 | Lori Webb, R.T. (R) and Tom Watson, RCVT
Healthcare organizations, clinicians and medical equipment manufacturers have long focused on the management and redu
mobile health apps, FTC, compliance tool, business guidance, privacy
News | Mobile Devices| April 25, 2016
The Federal Trade Commission (FTC) announced that it has created a Web-based guidance tool for developers of health-...
Siemens Sensis Vibe, hemodyanamics system

Siemens released the Sensis Vibe hemodyanamics system at ACC.16. The newer system offers better integration of cath lab data into cath lab reports and the electronic medical record (EMR).

Feature | ACC| April 25, 2016 | Jon Brubaker, MBA, RCVT, Tom Watson, BS, RCVT, and Sabrina Newell MS, RCS
There were several trends seen in new cardiovascular technologies showcased on the expo floor at the 2016 American...
Inventory management, analytics software, cardiology

An example of a page from GE Healthcare's Cloud analytics software, showing percentage use of a hospital's operating rooms by procedure type and showing a breakdown of surgical supplies in drill down for one of these procedures.

Feature | Analytics Software| April 15, 2016 | Dave Fornell
With all areas of healthcare now migrating to electronic medical record (EMR) platforms, the data they contain can be
Sponsored Content | Videos | Inventory Management| April 15, 2016
Healthcare reform is changing the way you provide care.
Sponsored Content | Videos | ACC| April 15, 2016
MDbuyline clinical analyst Tom Watson, BS, RCVT, explains the new technology trends he saw on the expo floor at ACC.1
Big data in cardiology, social media big data analytics, data mining

Big data, showing correlation between a CDC study on cardiovascular disease and a study conducted based on hostility in Twitter tweets. This demonstrates how big data from social media might be used to in new ways to evaluate population health.

Feature | Information Technology| April 10, 2016 | Dave Fornell
The buzz term “big data” has made a rapid entry onto the healthcare scene in the past couple years with promises of...
Overlay Init